Add to favorites:
Share:
This funding call aims to support research and development of antibodies and antibody-derived proteins to address infectious diseases with epidemic potential. The call focuses on advancing the understanding of prophylactic and therapeutic options for emerging and re-emerging viral infections. Proposals should address preclinical studies, GMP-quality test batch preparation, and first-in-human clinical safety studies. Targeted viruses include Arenaviridae (e.g., Lassa mammarenavirus), Hantaviridae (e.g., Hantaan virus), and others, with a focus on affordability and large-scale production for pandemic response.
Opening: 22-05-2025
Deadline(s): 18-09-2025
Data provided by Kooperationsstelle Wissenschaft
This funding opportunity represents a pre-agreed draft that has not yet been officially approved by the European Commission. The final, approved version is expected to be published in the first quarter of 2025. This draft is provided for informational purposes and may be used to preliminarily form consortia and develop project ideas, but it is offered without any guarantees or warranties.
Expected Outcome
• Improved understanding of antibody-based prophylactic and therapeutic options for epidemic-potential viruses
• Availability of experimental antibodies for prevention and treatment
• Candidate antiviral therapies for clinical deployment during epidemics and pandemics
Scope
• Development of antibodies and antibody-derived proteins targeting specific epidemic-potential viruses
• Preclinical in vitro and in vivo testing to demonstrate efficacy and safety
• Production of GMP-quality test batches within the EU/EEA
• Conducting first-in-human clinical safety studies
• Collaboration with regulatory bodies and endemic regions